Literature DB >> 23584132

Predictors of response to palliative care intervention for chronic nausea in advanced cancer outpatients.

Wadih Rhondali1, Sriram Yennurajalingam, Gary Chisholm, Jeanette Ferrer, Sun Hyun Kim, Jung Hun Kang, Marilene Filbet, Eduardo Bruera.   

Abstract

PURPOSE: Nausea is a frequent and distressing symptom in advanced cancer patients. The objective of this retrospective study was to determine predictors of response to palliative care consultation for chronic nausea in advanced cancer outpatients.
METHODS: Eligible patients included were outpatient supportive care center seen consecutively for an initial consultation and who had one follow-up visit within 30 days of the initial consultation. We reviewed the medical records of 1,273 consecutive patients, and 444 (35 %) were found to meet the eligibility criteria. All patients were assessed using the Edmonton Symptom Assessment Scale (ESAS). Nausea response was defined as an improvement of at least 30% between the initial visit and the first follow-up. We used logistic regression models to assess the possible predictors of improvement in nausea.
RESULTS: Overall, 112 of 444 patients (25%) experienced moderate/severe chronic nausea (ESAS item score ≥4/10). Higher baseline nausea intensity was significantly related to constipation (r = 0.158; p = 0.046) and all the symptoms assessed by the ESAS (p < 0.001). Sixty-eight of the 112 (61%) patients with moderate/severe nausea at baseline showed a significant improvement at the follow-up visit (p < 0.001). The main predictors for nausea response were improvement of fatigue (p = 0.005) and increased appetite (p = 0.003).
CONCLUSIONS: Baseline nausea was associated with all the ESAS symptom and improvement of fatigue and lack of appetite predicted a lower frequency of nausea at follow-up. More research is necessary to better understand the association between nausea severity and other symptoms and to predict which interventions will yield the best outcomes depending on the mix and severity of symptoms.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23584132      PMCID: PMC3895156          DOI: 10.1007/s00520-013-1805-8

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  41 in total

Review 1.  Treatment of nausea and vomiting in advanced cancer.

Authors:  M P Davis; D Walsh
Journal:  Support Care Cancer       Date:  2000-11       Impact factor: 3.603

Review 2.  Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer.

Authors:  F Joly; J Vardy; M Pintilie; I F Tannock
Journal:  Ann Oncol       Date:  2007-08-13       Impact factor: 32.976

3.  Multidisciplinary symptom control clinic in a cancer center: a retrospective study.

Authors:  E Bruera; M Michaud; A Vigano; C M Neumann; S Watanabe; J Hanson
Journal:  Support Care Cancer       Date:  2001-05       Impact factor: 3.603

4.  Detecting alcoholism. The CAGE questionnaire.

Authors:  J A Ewing
Journal:  JAMA       Date:  1984-10-12       Impact factor: 56.272

Review 5.  Using the Liverpool Care Pathway for a dying patient.

Authors:  Mary P McNicholl; Kathleen Dunne; Angela Garvey; Rose Sharkey; Amanda Bradley
Journal:  Nurs Stand       Date:  2006 May 31-Jun 6

6.  The management of nausea and vomiting in advanced cancer.

Authors:  Kathryn Hamling
Journal:  Int J Palliat Nurs       Date:  2011-07

7.  Defining the clinically important difference in pain outcome measures.

Authors:  J T Farrar; R K Portenoy; J A Berlin; J L Kinman; B L Strom
Journal:  Pain       Date:  2000-12-01       Impact factor: 6.961

8.  An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer.

Authors:  Jeffrey Stephenson; Andrew Davies
Journal:  Support Care Cancer       Date:  2005-10-15       Impact factor: 3.603

Review 9.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  A review of the reliability and validity of the Edmonton Symptom Assessment System.

Authors:  L A Richardson; G W Jones
Journal:  Curr Oncol       Date:  2009-01       Impact factor: 3.677

View more
  5 in total

1.  Understanding Symptom Burden in Patients With Advanced Cancer Living in Rural Areas.

Authors:  Stephanie Gilbertson-White; Yelena Perkhounkova; Seyedehtanaz Saeidzadeh; Maria Hein; Rachel Dahl; Andrean Simons-Burnett
Journal:  Oncol Nurs Forum       Date:  2019-07-01       Impact factor: 2.172

Review 2.  Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting.

Authors:  Hanno Riess; Cihan Ay; Rupert Bauersachs; Cecilia Becattini; Jan Beyer-Westendorf; Francis Cajfinger; Ian Chau; Alexander T Cohen; Alok A Khorana; Anthony Maraveyas; Marcos Renni; Annie M Young
Journal:  Oncologist       Date:  2018-04-12

Review 3.  Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?

Authors:  Rita J Wickham
Journal:  J Adv Pract Oncol       Date:  2020-07-01

4.  Integrative Oncology Outpatient Consultations: Long-Term Effects on Patient-Reported Symptoms and Quality of Life.

Authors:  Gabriel Lopez; Wenli Liu; Jennifer McQuade; Richard T Lee; Amy R Spelman; Bryan Fellman; Yisheng Li; Eduardo Bruera; Lorenzo Cohen
Journal:  J Cancer       Date:  2017-06-03       Impact factor: 4.207

5.  Active surveillance of chemotherapy-related symptom burden in ambulatory cancer patients via the implementation of electronic patient-reported outcomes and sensor-enabled vital signs capture: protocol for a decentralised feasibility pilot study.

Authors:  Anaeze C Offodile; Sandra R DiBrito; Janice P Finder; Sanjay Shete; Sanchita Jain; Domenica A Delgado; Christopher J Miller; Elenita Davidson; Michael J Overman; Susan K Peterson
Journal:  BMJ Open       Date:  2022-04-05       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.